Obsidian Therapeutics
PublicObsidian Therapeutics is now publicly traded
The data on this page reflects Obsidian Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Equity
Apr 14, 2026
Est. Valuation at Exit
$763.5M
Total Funding Raised
$675M
Company Overview
Obsidian Therapeutics is a biotechnology company that develops engineered cell and gene therapies for cancer treatment using a proprietary protein-regulation platform.
Sector
Biotech
Verticals
HealthTech, Life Sciences, Oncology
AI Layer
Non-AI
Keywords
Obsidian Therapeutics Comparables
Compare Obsidian Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Turnstone Biologics | 83% | |
| Iovance Biotherapeutics | 79% | |
| Intima Bioscience | 77% |
For institutional investors. Book with your work email.
Obsidian Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Apr 14, 2026 | ||||
| Series C | Apr 3, 2024 | ||||
| Series B | Sep 9, 2021 | ||||
| Series A | Dec 6, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Obsidian Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Private Equity |
| Soleus Capital | Series B |
| Surveyor Capital | Series C, Series B |
| Janus Henderson Group | Series C, Private Equity |
| Balyasny Asset Management L.P. | Private Equity |
| RA Capital Management | Series C, Series B, Private Equity |
| TCG Crossover | Series C, Private Equity, Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 5, 2026
Obsidian Therapeutics, Inc. is to present updated amsoki-cel (OBX-115) Phase 1/2 data in patients with immune-checkpoint inhibitor-resistant advanced melanoma at the SITC 2026 Annual Meeting in Arizona on Nov 7th '26.
For institutional investors. Book with your work email.
Obsidian Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.